cilgavimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiviral, monoclonal antibodies 5684 2420563-99-9

Description:

MoleculeDescription

Molfile

Synonyms:

  • cilgavimab
  • cilgavimab (genetical recombination)
  • AZD1061
  • COV2-2130
  • AZD-1061
Cilgavimab is a recombinant human IgG1 monoclonal antibody used in combination with tixagevimab for the treatment of COVID-19.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 25, 2022 EMA AstraZeneca AB
Aug. 30, 2022 PMDA AstraZeneca K.K.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J06BD03 ANTIINFECTIVES FOR SYSTEMIC USE
IMMUNE SERA AND IMMUNOGLOBULINS
IMMUNOGLOBULINS
Antiviral monoclonal antibodies

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
COVID-19 indication 840539006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Spike glycoprotein Glycoprotein BINDING AGENT Kd 10.89 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL4650258 ChEMBL_ID
C000714149 MESH_SUPPLEMENTAL_RECORD_UI
C000714207 MESH_SUPPLEMENTAL_RECORD_UI
11329 IUPHAR_LIGAND_ID
DB16393 DRUGBANK_ID
018904 NDDF
4041037 VANDF
C5432263 UMLSCUI
11777 INN_ID
D11994 KEGG_DRUG
2587306 RXNORM
40136 MMSL
d09833 MMSL
1KUR4BN70F UNII

Pharmaceutical products:

None